Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Otsuji (koshigaya, Japan), K. Sugiyama (koshigaya, Japan), H. Arifuku (koshigaya, Japan), K. Nakano (koshigaya, Japan), H. Watanabe (koshigaya, Japan), T. Wakayama (koshigaya, Japan), K. Koyama (koshigaya, Japan), H. Hirata (koshigaya, Japan), Y. Fukushima (koshigaya, Japan). Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). 747

Member's Comments

No comment yet.

Related content which might interest you: Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 The frequency of the respiratory comorbidities in patients (pts) with rheumatoid arthritis (RA) Source: Virtual Congress 2021 – What's new in respiratory problems in rare and systemic diseases Year: 2021 The lung in rheumatoid arthritis: drugs versus underlying disease Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective Year: 2009 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 The diagnostic of the respiratory pathology in patients with rheumatoid arthritis (RA) Source: International Congress 2016 – The best clinical approach to lung diseases Year: 2016 Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis Source: Eur Respir J 2004; 24 : 708 Year: 2004 Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Duration of rheumatoid arthritis and the risk of developing interstitial lung disease Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020 Year: 2021 Are smoking and COPD associated with ILD onset in rheumatoid arthritis? Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients Source: Eur Respir J 2014; 44: 1082-1085 Year: 2014 Pulmonary involvement in patients with rheumatoid arthritis Source: Eur Respir J 2006; 28: Suppl. 50, 381s Year: 2006 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Predicting outcomes in rheumatoid arthritis related interstitial lung disease Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018 Year: 2019